ipamorelin growth hormone secretagogue ghrelin receptor Ghrelin's modulation of receptors in primary glioblastoma and meningioma: A comprehensive in-vitro study ipamorelin growth hormone secretagogue ghrelin

doi: 10.1016/j.funbio.2021.03.006 41 LeeE.KimJ

Goodman, A.L

10.1186/s40001-024-01747-1 466 WangL.WangX.ZhangG.MaY.ZhangQ.LiZ.et al

Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research